First therapy to treat transplant patients with post-transplant lymphoproliferative disease (Cell and Gene Therapy Catapult - Regulatory Round-up – October 2022)
Fiche du document
25 janvier 2023
- handle: 10670/1.i3wjl7
Sujets proches
TherapyCiter ce document
adelage, « First therapy to treat transplant patients with post-transplant lymphoproliferative disease (Cell and Gene Therapy Catapult - Regulatory Round-up – October 2022) », ELSIBI, ID : 10670/1.i3wjl7
Métriques
Partage / Export
Résumé
At its October 2022 meeting, EMA’s human medicines committee (CHMP) has recommended a marketing authorisation in the European Union (EU) for Ebvallo (tabelecleucel) for the treatment of adult and pediatric patients who have a serious complication following solid organ transplantation (SOT) or bone marrow transplantation (hematopoietic cell transplant - HCT) called EBV+ PTLD. Please find more details here. See all of Catapult's Regulatory Round-up for October 2022 here. Published on the 7th of...